Home > Insights > Blogs > Life Sciences Decoded > Blog Browse: CBD drugs moved to Schedule 5; no promises for cannabis

Blog Browse: CBD drugs moved to Schedule 5; no promises for cannabis

Diane Romza-Kutz October 1, 2018

The DEA has moved CBD prescription drugs with THC levels below .01% to a Schedule 5 drug after the FDA’s approval of Epidolex. However, despite the reschedule, cannabis still remains a Schedule 1 substance.

Read the full post, "CBD drugs moved to Schedule 5; no promises for cannabis," on our Tracking Cannabis blog.